Gobivaz Biosimilar Earns EEA Approval, Expanding Access to Anti-TNF Therapy
Reykjavik & London, November 2025 Alvotech and Advanz Pharma have received marketing approval across the European Economic Area (EEA)...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Reykjavik & London, November 2025 Alvotech and Advanz Pharma have received marketing approval across the European Economic Area (EEA)...
Dateline – November 17 2025 | Minneapolis & Miami PetVivo Holdings, Inc. announced that its exclusive AI-technology partner, Digital...
